Accelerate Diagnostics Sees Prelim. Q4 Sales $3.3M vs $3.92M Est., FY21 Sales $11.8M vs $12.28M Est.

by Hal Lindon, Benzinga Editor

January 13, 2022 9:17 AM | 5 seconds read |

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.